Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Filali-Ansary, Aziz, Lunven, Catherine, Turpault, Sandrine, Beyer, Yann-Joel, O'Brien, Amy, Delfolie, Astrid, Boyanova, Neli, Sanderink, Ger-Jan, Baldinetti, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/
https://www.ncbi.nlm.nih.gov/pubmed/27015245
http://dx.doi.org/10.1097/FTD.0000000000000302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/
https://www.ncbi.nlm.nih.gov/pubmed/27015245
http://dx.doi.org/10.1097/FTD.0000000000000302

Ejemplares similares